Quantifying Pulmonary Inflammation in Cystic Fibrosis with Positron Emission Tomography

Overview

Journal Am J Respir Crit Care Med

Specialty Critical Care

Date 2006 Mar 18

PMID 16543553

Citations 39

Authors

Delphine L Chen

Thomas W Ferkol

Mark A Mintun

Jessica E Pittman

Daniel B Rosenbluth

Daniel P Schuster

Affiliations

Soon will be listed here.

Abstract

Rationale: Although infection contributes to morbidity in patients with cystic fibrosis (CF), the host inflammatory response is also an important cause of progressive pulmonary function deterioration. Quantifying the inflammatory burden in these patients is challenging and often requires invasive procedures. Positron emission tomographic imaging with [18F]fluorodeoxyglucose ([18FDG]) could be used as a noninvasive alternative to quantify lung inflammation.

Objective: To determine the relationships among lung [18F]FDG uptake, bronchoalveolar lavage (BAL) neutrophil concentrations, and pulmonary function in patients with CF.

Methods: Twenty patients and seven healthy volunteers were studied. A subset of seven patients also consented to undergo BAL. The uptake of [18F]FDG by the lungs was measured as the net influx rate constant Ki. Patients were stratified by rate of decline in pulmonary function into stable, intermediate, and rapidly declining groups. Ki was compared among groups and was correlated against neutrophil concentrations in BAL fluid.

Results: Ki was significantly elevated (p<0.05) among patients with CF as a whole compared with healthy control subjects (0.0015+/-0.0009 versus 0.0007+/-0.0002 ml blood/ml lung/min) but especially in patients with rapidly declining pulmonary function (0.0022+/-0.0011 ml blood/ml lung/min). Ki correlated positively with the number of neutrophils present in BAL fluid.

Conclusion: Imaging with [18F]fluorodeoxyglucose and positron emission tomography can be used to assess inflammatory burden in patients with CF. Elevations in Ki may be able to identify patients with more aggressive disease and may be useful in monitoring changes in inflammatory burden in response to novel treatments.

Citing Articles

Application of low-dose FDG-PET/MRI for quantification of lung changes in pediatric patients with cystic fibrosis: a new inflammatory index.

Schwarz R, Schafer J, Utz P, Graepler-Mainka U, Dittmann H, Kraus M Quant Imaging Med Surg. 2025; 15(1):189-202.

PMID: 39838989 PMC: 11744157. DOI: 10.21037/qims-24-989.

Modulation of low-dose ozone and LPS exposed acute mouse lung inflammation by IF1 mediated ATP hydrolysis inhibitor, BTB06584.

Singh P, Aulakh G Front Immunol. 2023; 14:1126574.

PMID: 36993977 PMC: 10040673. DOI: 10.3389/fimmu.2023.1126574.

2-deoxy-2-[F]fluoro-D-glucose Positron Emission Tomography to Monitor Lung Inflammation and Therapeutic Response to Dexamethasone in a Murine Model of Acute Lung Injury.

Mannes P, Barnes C, Latoche J, Day K, Nedrow J, Lee J Mol Imaging Biol. 2023; 25(4):681-691.

PMID: 36941514 PMC: 10027262. DOI: 10.1007/s11307-023-01813-w.

Increased sputum lactate during oral glucose tolerance test in cystic fibrosis.

Jensen P, Nielsen B, Kolpen M, Pressler T, Faurholt-Jepsen D, Mathiesen I APMIS. 2022; 130(8):535-539.

PMID: 35635299 PMC: 9545947. DOI: 10.1111/apm.13233.

Overview of positron emission tomography in functional imaging of the lungs for diffuse lung diseases.

Gulhane A, Chen D Br J Radiol. 2021; 95(1132):20210824.

PMID: 34752146 PMC: 9153708. DOI: 10.1259/bjr.20210824.

References

Meller J, Strutz F, Siefker U, Scheel A, Sahlmann C, Lehmann K . Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003; 30(5):730-6. DOI: 10.1007/s00259-003-1144-y. View

DORING G, Worlitzsch D . Inflammation in cystic fibrosis and its management. Paediatr Respir Rev. 2003; 1(2):101-6. DOI: 10.1053/prrv.2000.0030. View

Gibson R, Burns J, Ramsey B . Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003; 168(8):918-51. DOI: 10.1164/rccm.200304-505SO. View

Chen D, Schuster D . Positron emission tomography with [18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003; 286(4):L834-40. DOI: 10.1152/ajplung.00339.2003. View

Jones H, Donovan T, Goddard M, McNeil K, Atkinson C, Clark J . Use of 18FDG-pet to discriminate between infection and rejection in lung transplant recipients. Transplantation. 2004; 77(9):1462-4. DOI: 10.1097/01.tp.0000121767.05724.33. View

Rosenbluth D, Wilson K, Ferkol T, Schuster D . Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest. 2004; 126(2):412-9. DOI: 10.1378/chest.126.2.412. View

Chen D, Mintun M, Schuster D . Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injury. J Nucl Med. 2004; 45(9):1583-90. View

Koehler D, Downey G, Sweezey N, Tanswell A, Hu J . Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol. 2004; 31(4):377-81. DOI: 10.1165/rcmb.2004-0124TR. View

Bonnel A, Song S, Kesavarju K, Newaskar M, Paxton C, Bloch D . Quantitative air-trapping analysis in children with mild cystic fibrosis lung disease. Pediatr Pulmonol. 2004; 38(5):396-405. DOI: 10.1002/ppul.20091. View

10.

Hunninghake G, Kawanami O, Ferrans V, YOUNG Jr R, Roberts W, Crystal R . Characterization of the inflammatory and immune effector cells in the lung parenchyma of patients with interstitial lung disease. Am Rev Respir Dis. 1981; 123(4 Pt 1):407-12. DOI: 10.1164/arrd.1981.123.4.407. View

11.

PATLAK C, Blasberg R, Fenstermacher J . Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983; 3(1):1-7. DOI: 10.1038/jcbfm.1983.1. View

12.

PATLAK C, Blasberg R . Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985; 5(4):584-90. DOI: 10.1038/jcbfm.1985.87. View

13.

. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis. 1990; 141(5 Pt 2):S169-202. DOI: 10.1164/ajrccm/141.5_Pt_2.S169. View

14.

Kerem E, Reisman J, Corey M, Canny G, Levison H . Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992; 326(18):1187-91. DOI: 10.1056/NEJM199204303261804. View

15.

Jorens P, Hebert C, Ueki I, Nadel J . Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol. 1993; 264(4 Pt 1):L413-8. DOI: 10.1152/ajplung.1993.264.4.L413. View

16.

Jones H, Clark R, Rhodes C, Schofield J, Krausz T, Haslett C . In vivo measurement of neutrophil activity in experimental lung inflammation. Am J Respir Crit Care Med. 1994; 149(6):1635-9. DOI: 10.1164/ajrccm.149.6.7516252. View

17.

Konstan M, Hilliard K, Norvell T, Berger M . Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 1994; 150(2):448-54. DOI: 10.1164/ajrccm.150.2.8049828. View

18.

Konstan M, Byard P, Hoppel C, DAVIS P . Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995; 332(13):848-54. DOI: 10.1056/NEJM199503303321303. View

19.

Eigen H, Rosenstein B, Fitzsimmons S, Schidlow D . A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr. 1995; 126(4):515-23. DOI: 10.1016/s0022-3476(95)70343-8. View

20.

Ramsey B . Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996; 335(3):179-88. DOI: 10.1056/NEJM199607183350307. View